Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom.
about
Venom immunotherapy for preventing allergic reactions to insect stingsInsect sting anaphylaxisStinging insect allergy: current perspectives on venom immunotherapyRisk associated with bee venom therapy: a systematic review and meta-analysisDiagnostics in Hymenoptera venom allergy: current concepts and developments with special focus on molecular allergy diagnosticsBasophil sensitivity through CD63 or CD203c is a functional measure for specific immunotherapyAnaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology.Congruence of the current practices in Hymenoptera venom allergic patients in Poland with EAACI guidelines.Anaphylaxis: clinical concepts and research priorities.Quality-of-life in insect venom allergy: validation of the Turkish version of the "Vespid Allergy Quality of Life Questionnaire" (VQLQ-T).Importance of basophil activation testing in insect venom allergy.Specific immunotherapy using Hymenoptera venom: systematic review.Clinical immunology review series: an approach to desensitization.Hymenoptera venom immunotherapy.Managing anxiety related to anaphylaxis in childhood: a systematic review.Quality of life measures for food allergy.Food allergy and quality of life: what have we learned?Venom immunotherapy: an updated review.Venom immunotherapy: clinical efficacy, safety and contraindications.EAACI Guidelines on Allergen Immunotherapy: Hymenoptera venom allergy.Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis.Anaphylaxis: epidemiology, aetiology and relevance for the clinic.Anxiety and Atopic Disease: Comorbidity in a Youth Mental Health Setting.Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guidelines.Honeybee venom immunotherapy: a comparative study using purified and nonpurified aqueous extracts in patients with normal Basal serum tryptase concentrations.Fatal Anaphylaxis: Mortality Rate and Risk Factors.Hymenoptera Venom Immunotherapy: Tolerance and Efficacy of an Ultrarush Protocol versus a Rush and a Slow Conventional ProtocolHealth-related quality of life in Polish adolescents with Hymenoptera venom allergy treated with venom immunotherapy.Assessment of quality of life in children with peanut allergy.Epipen use: good clinical practice.Risk assessment of Hymenoptera re-sting frequency: implications for decision-making in venom immunotherapy.Immunotherapy for hymenoptera venom allergy: too expensive for European health care?Managing insect sting allergy. The ins and outs of venom immunotherapy.Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice.Online version of the food allergy quality of life questionnaire-adult form: validity, feasibility and cross-cultural comparison.The compliance and burden of treatment with the epinephrine auto-injector in food-allergic adolescents.Antiallergic drugs and quality of life.Psychosomatic or allergic symptoms? High levels for somatization in patients with drug intolerance.Self-medication of anaphylactic reactions due to Hymenoptera stings-an EAACI Task Force Consensus Statement.Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population.
P2860
Q24198148-75AD0F14-8D60-4CC2-B1A5-02269AB90FAFQ24672123-BE81A8CF-D8BC-4027-9256-561D93C8C5E8Q26801123-4CFDBF0C-4284-466E-B9E7-9A44352AF72EQ28547393-304E819D-7FC1-4CB9-A9B3-DBC41C1EF392Q33607136-39418B44-D528-4027-A8B2-EF8CCC1F2C72Q33702206-4F4847D6-A593-46BB-B8B6-22F5A3C92D89Q34423618-CCDBB458-BD4F-49AA-87ED-765C216A1703Q35674378-9C130D62-E9D0-4D0C-804D-63AD144D0855Q36466735-90CE5BFE-090B-496A-9BA8-DE8342D31A86Q36894802-1C5CD774-D6FB-4639-8B65-43C50613B4DEQ37479659-362EADC6-1BBF-43C1-AF15-C25EC90EB0ECQ37761635-3B2B9CE4-FACC-4CAA-ABF4-DC54FEE34A42Q37822834-A5C8D91E-AB8D-4591-9079-D2478127328CQ37842330-7DDB8F0D-9CF9-41F2-8EA0-F153D91D48ABQ37946899-4BBB5EED-A9EE-4430-AEFD-EA6745EA0968Q37975285-691624D7-27CB-4C45-9C2D-1427E7F6C393Q38152278-8C29E14B-FCFC-4995-AC3D-B0A0FEE33167Q38220704-8DF8D240-DD7C-4C45-A729-35A18F8134AEQ38505192-9A22BA14-92B7-41CC-9B4B-B9634408DB43Q38658310-E967A684-3AF5-4258-8CC5-9BE7C64269E6Q39000691-384C89A2-D8DD-4529-984E-BE77416FFA70Q39340740-8B841DD1-878D-4830-A0F4-A097F56A948BQ39448549-286441B9-6B1C-4D28-B4B0-3B0C3F375EC3Q39716681-1AA2CDE1-98F6-48BB-AE3A-97DAC128A641Q40582052-0F3A1789-E6CA-4C8E-BA5A-06150B57F89FQ41560811-81FFA1F2-45C2-47D9-B72F-34ABAFDAAC34Q42121666-8119E04B-7926-4781-BAD4-CB051CAFEBD9Q42686774-FA8BDAF1-044F-4F12-AD76-E2A1B8AC3AA5Q44528729-F4E159E4-1FBB-47ED-A019-CAD0324A7A73Q44804594-407F1CFC-EB83-4459-B2E1-23FE731C3A61Q45419495-9F7368CA-CE82-4275-8637-7D721EC651DCQ46147776-5521E7DA-18A6-4027-9B42-6B5017F1B94FQ46655877-272B781F-96D3-460A-B73C-58CB25576F32Q46787767-35844639-83CC-41CA-850D-9ED4575D235EQ47314527-F9270845-18C2-4703-9D2F-3F4463BA0C05Q47659816-4BAB7695-7164-4885-9739-3C24174C69B7Q47755374-CA0D4057-60E8-4941-9B90-1AF2B56F5091Q48247013-ED046B4E-C5BF-44E2-84BD-3A21A216FDFBQ51533907-45B04DA5-3EEC-49E8-88D0-1AE0E1DB3065Q51726343-8AEF0C25-3C34-427A-A829-8F7E75C9B5C0
P2860
Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Venom immunotherapy improves h ...... lergic to yellow jacket venom.
@en
Venom immunotherapy improves h ...... lergic to yellow jacket venom.
@nl
type
label
Venom immunotherapy improves h ...... lergic to yellow jacket venom.
@en
Venom immunotherapy improves h ...... lergic to yellow jacket venom.
@nl
prefLabel
Venom immunotherapy improves h ...... lergic to yellow jacket venom.
@en
Venom immunotherapy improves h ...... lergic to yellow jacket venom.
@nl
P2093
P921
P356
P1476
Venom immunotherapy improves h ...... lergic to yellow jacket venom.
@en
P2093
Anthony E J Dubois
Jan G R De Monchy
Joanne N G Oude Elberink
Sicco Van Der Heide
P304
P356
10.1067/MAI.2002.125827
P407
P577
2002-07-01T00:00:00Z